(4-苄基哌啶-1-基)-(2-甲氧基-4-甲硫基苯基)甲酮 | 349087-34-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (4-苄基哌啶-1-基)-(2-甲氧基-4-甲硫基苯基)甲酮
• 英文名称: Piperidine, 1-(2-methoxy-4-(methylthio)benzoyl)-4-(phenylmethyl)-
• 英文别名: (4-benzylpiperidin-1-yl)-(2-methoxy-4-methylsulfanylphenyl)methanone
• CAS: 349087-34-9
• 化学式: C₂₁H₂₅NO₂S
• mdl: MFCD02038777
• 分子量: 355.5
• InChiKey: OMGLGPKQUFSRNN-UHFFFAOYSA-N

物化性质

• 溶解度：
  可溶于DMSO（高达25mg/ml）或乙醇（高达20mg/ml）。

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  25
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  54.8
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险品标志：
  N
• 危险类别码：
  R50/53
• 危险品运输编号：
  UN 3077 9/PG 3
• 安全说明：
  S60,S61

文献信息

• COMPOSITION COMPRISING A SPECIFIC P38A INHIBITOR AND AN AGENT THAT INDUCES CHROMOSOME INSTABILITY AND MEDICAL USES THEREOF
  申请人：Fundació Institut de Recerca Biomèdica (IRB Barcelona)

  公开号：EP3415164A1

  公开（公告）日：2018-12-19

  The present invention relates to compositions comprising a specific p38α inhibitor and an agent that induces chromosome instability, wherein preferably the specific p38α inhibitor has a half maximal inhibitory concentration (IC50) equal to or less than 40 nM. The invention also relates to the above compositions or to a specific p38α inhibitor for use in the treatment of breast cancer, wherein the breast cancer is characterised by a high degree of chromosome instability. Finally, the invention relates to a method for identifying a breast cancer patient who responds to a treatment with the above compositions or with a specific p38α inhibitor, wherein the breast cancer is characterised by a high degree of chromosome instability, and a method for selecting a treatment for a breast cancer patient.

  本发明涉及包含特异性 p38α 抑制剂和诱导染色体不稳定性的制剂的组合物，其中优选特异性 p38α 抑制剂的半最大抑制浓度（IC50）等于或小于 40 nM。本发明还涉及上述组合物或用于治疗乳腺癌的特异性 p38α 抑制剂，其中乳腺癌的特征是染色体高度不稳定。最后，本发明涉及一种确定对上述组合物或特定 p38α 抑制剂治疗有反应的乳腺癌患者的方法（其中乳腺癌的特征是染色体高度不稳定），以及一种为乳腺癌患者选择治疗方法的方法。
• Medicament for treatment of liver cancer
  申请人：Zender Lars

  公开号：US10441577B2

  公开（公告）日：2019-10-15

  The invention provides a pharmaceutical composition comprising Sorafenib in combination with an inhibitor of a specific kinase inhibitor as a medicament for the treatment or prevention of liver cancer.

  本发明提供了一种药物组合物，该组合物由索拉非尼与一种特异性激酶抑制剂组合而成，作为治疗或预防肝癌的药物。
• Optimized peptides for targeting human nerves and their use in image guided surgery, diagnostics and therapeutic
  申请人：The Regents of the University of California

  公开号：US11299515B2

  公开（公告）日：2022-04-12

  The present invention provides methods for guiding preservation of human neurons or human nerves during surgery by administering a fluorescently-labeled peptide that specifically binds to the human neurons or human nerves. The invention further provides human neuron or nerve targeting molecules comprising fluorescently-labeled peptides that specifically bind to human neurons or human nerves and compositions thereof.

  本发明提供了在手术过程中通过施用能与人神经元或人神经特异性结合的荧光标记肽来指导保存人神经元或人神经的方法。本发明进一步提供了人类神经元或神经靶向分子，包括特异性结合人类神经元或人类神经的荧光标记肽及其组合物。
• Methods and compounds for the treatment or prevention of severe influenza
  申请人：Orph Pharma IP Company Limited

  公开号：US11339207B2

  公开（公告）日：2022-05-24

  A p38 MAPK inhibitor for use in the treatment or prevention of severe influenza in a human patient. In some embodiments, the severe influenza maybe characterised by hypercytokinemia involving elevated levels of one or more pro-inflammatory cytokines. The p38 MAP kinase inhibitor may act to inhibit the release of such pro-inflammatory mediators from endothelial cells. In some embodiments, the p38 MAP kinase inhibitor may inhibit the release of IP 10 from endothelial cells, preferably in a dose-dependent manner.

  用于治疗或预防人类患者重症流感的 p38 MAPK 抑制剂。在某些实施方案中，重症流感的特征可能是一种或多种促炎细胞因子水平升高的高细胞因子血症。p38 MAP 激酶抑制剂可抑制内皮细胞释放此类促炎介质。在某些实施方案中，p38 MAP 激酶抑制剂可抑制内皮细胞释放 IP 10，最好是以剂量依赖的方式。
• CONTROLLED-RELEASE APOPTOSIS MODULATING COMPOSITIONS AND METHODS FOR THE TREATMENT OF OTIC DISORDERS
  申请人：Otonomy, Inc.

  公开号：EP2296632A2

  公开（公告）日：2011-03-23